Regulation of the AKT/mTOR signaling kinases and extracellular signal-regulated kinase (ERK) has previously been observed in response to SFN treatment in breast cancer, prostate cancer, and hepatoma6, 13, 14. This evidence concerns the gene MTOR and prostate carcinoma.